{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:40:11Z","timestamp":1782837611226,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Prime Focus"},{"name":"Ashfield Healthcare Communications"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jns.2019.116426","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T11:21:26Z","timestamp":1565695286000},"page":"116426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results"],"prefix":"10.1016","volume":"406","author":[{"given":"Maria Jos\u00e9","family":"S\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Cec\u00edlia","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Martins","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Pinto-Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3\u20134","key":"10.1016\/j.jns.2019.116426_bb0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000360528","article-title":"Multiple sclerosis: current knowledge and future outlook","volume":"72","author":"Kamm","year":"2014","journal-title":"Eur. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2019.116426_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.362","article-title":"An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis","volume":"5","author":"Garg","year":"2015","journal-title":"Brain Behav."},{"key":"10.1016\/j.jns.2019.116426_bb0015","author":"Atlas of MS","year":"2013","journal-title":"Mapping Multiple Sclerosis around the World, 2013."},{"issue":"2_suppl","key":"10.1016\/j.jns.2019.116426_bb0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458517708667","article-title":"New insights into the burden and costs of multiple sclerosis in Europe: results for Portugal","volume":"23","author":"Sa","year":"2017","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.jns.2019.116426_bb0025","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1586\/14737167.2015.1067141","article-title":"The indirect costs of multiple sclerosis: systematic review and meta-analysis","volume":"15","author":"Stawowczyk","year":"2015","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"4","key":"10.1016\/j.jns.2019.116426_bb0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000337534","article-title":"Capture-recapture as a potentially useful procedure for assessing prevalence of multiple sclerosis: methodologic exercise using Portuguese data","volume":"38","author":"de Sa","year":"2012","journal-title":"Neuroepidemiology"},{"issue":"7","key":"10.1016\/j.jns.2019.116426_bb0035","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00415-006-0132-0","article-title":"The prevalence of multiple sclerosis in the District of Santarem, Portugal","volume":"253","author":"De Sa","year":"2006","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2019.116426_bb0040","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/895163","article-title":"MS prevalence and patients' characteristics in the District of Braga, Portugal","volume":"2015","author":"Figueiredo","year":"2015","journal-title":"Neurol. Res. Int."},{"issue":"5","key":"10.1016\/j.jns.2019.116426_bb0045","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2019.116426_bb0050","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.jns.2019.116426_bb0055","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1348-0421.1982.tb00254.x","article-title":"Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera","volume":"26","author":"Taguchi","year":"1982","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.jns.2019.116426_bb0060","series-title":"Tysabri\u00ae (natalizumab) [summary of product characteristics]","year":"2016"},{"issue":"20","key":"10.1016\/j.jns.2019.116426_bb0065","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jns.2019.116426_bb0070","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jns.2019.116426_bb0075","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1","volume":"70","author":"Bozic","year":"2011","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2019.116426_bb0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2019.116426_bb0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J. Clin. Virol."},{"issue":"6","key":"10.1016\/j.jns.2019.116426_bb0090","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"issue":"22","key":"10.1016\/j.jns.2019.116426_bb0095","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","article-title":"Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort","volume":"78","author":"Trampe","year":"2012","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2019.116426_bb0100","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00415-012-6487-5","article-title":"Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy","volume":"259","author":"Outteryck","year":"2012","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2019.116426_bb0105","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1590\/0004-282X20130121","article-title":"Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive","volume":"71","author":"Fragoso","year":"2013","journal-title":"Arq. Neuropsiquiatr."},{"issue":"11","key":"10.1016\/j.jns.2019.116426_bb0110","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.jns.2019.116426_bb0115","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1017\/cjn.2014.32","article-title":"Anti-JC virus antibody prevalence in Canadian MS patients","volume":"41","author":"Bhan","year":"2014","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.jns.2019.116426_bb0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jns.2015.11.044","article-title":"JC virus seroprevalence and seroconversion in multiple sclerosis cohort: a Middle-Eastern study","volume":"360","author":"Alroughani","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jns.2019.116426_bb0125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/ane.12475","article-title":"Anti-JC virus seroprevalence in a Finnish MS cohort","volume":"133","author":"Kolasa","year":"2016","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.jns.2019.116426_bb0130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/eci.12721","article-title":"Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort","volume":"47","author":"Dominguez-Mozo","year":"2017","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.jns.2019.116426_bb0135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jns.2016.03.050","article-title":"Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain","volume":"365","author":"Aladro","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jns.2019.116426_bb0140","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ene.12304","article-title":"Anti-JC virus (JCV) antibody prevalence in the JCV epidemiology in MS (JEMS) trial","volume":"21","author":"Bozic","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2019.116426_bb0145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jns.2013.11.031","article-title":"JCV epidemiology in MS (JEMS)\u2014epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients\u2014Portuguese data","volume":"337","author":"da Silva","year":"2014","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2019.116426_bb0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2019.116426_bb0155","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jocn.2017.08.006","article-title":"Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese multiple sclerosis population","volume":"45","author":"Correia","year":"2017","journal-title":"J. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.jns.2019.116426_bb0160","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X19303582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X19303582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:48:41Z","timestamp":1758383321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X19303582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":32,"alternative-id":["S0022510X19303582"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2019.116426","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2019.116426","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116426"}}